Circular RNA hsa-circ-000881 suppresses the progression of lung adenocarcinoma
Circ-000881
PRICKLE2
lung adenocarcinoma (LUAD)
miR-665
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
entrez:
14
4
2021
pubmed:
15
4
2021
medline:
15
4
2021
Statut:
ppublish
Résumé
Circular RNA (circRNA) has become a new focus in the field of tumor biology research in recent years. Many circRNAs have been showed to play an important role in the progression of lung adenocarcinoma (LUAD). In this work, we studied the oncological role of hsa-circ-000881 in LUAD and attempted to explore the related mechanism. The relative expressions of hsa-circ-000881, miR-665, and PRICKLE2 were detected by RT-qPCR or western blot. Functional assays were conducted to analyze the role of hsa-circ-000881 in the proliferation, migration, and invasion of LUAD cells. A luciferase reporter assay was performed to verify whether hsa-circ-000881, miR-665, and PRICKLE2 interact with each other. Circ-000881 was remarkably downregulated in LUAD. Overexpression of circ-000881 attenuated cell growth, migration, and invasion, whereas its knockdown enhanced the malignancy of LUAD cells. The results of luciferase reporter assay and bioinformatics analysis confirmed that circ-000881 served as a sponge for miR-665, and PRICKLE2 was a direct target of miR-665.Overexpression of miR-665 or silencing of PRICKLE2 abolished circ-000881-mediated inhibition of malignant tumor behavior in LUAD cells. Circ-000881 has inhibitory effects on LUAD via a miR-665/PRICKLE2 axis, suggesting that circ-000881 may be an underlying therapeutic target for LUAD.
Sections du résumé
BACKGROUND
BACKGROUND
Circular RNA (circRNA) has become a new focus in the field of tumor biology research in recent years. Many circRNAs have been showed to play an important role in the progression of lung adenocarcinoma (LUAD). In this work, we studied the oncological role of hsa-circ-000881 in LUAD and attempted to explore the related mechanism.
METHODS
METHODS
The relative expressions of hsa-circ-000881, miR-665, and PRICKLE2 were detected by RT-qPCR or western blot. Functional assays were conducted to analyze the role of hsa-circ-000881 in the proliferation, migration, and invasion of LUAD cells. A luciferase reporter assay was performed to verify whether hsa-circ-000881, miR-665, and PRICKLE2 interact with each other.
RESULTS
RESULTS
Circ-000881 was remarkably downregulated in LUAD. Overexpression of circ-000881 attenuated cell growth, migration, and invasion, whereas its knockdown enhanced the malignancy of LUAD cells. The results of luciferase reporter assay and bioinformatics analysis confirmed that circ-000881 served as a sponge for miR-665, and PRICKLE2 was a direct target of miR-665.Overexpression of miR-665 or silencing of PRICKLE2 abolished circ-000881-mediated inhibition of malignant tumor behavior in LUAD cells.
CONCLUSIONS
CONCLUSIONS
Circ-000881 has inhibitory effects on LUAD via a miR-665/PRICKLE2 axis, suggesting that circ-000881 may be an underlying therapeutic target for LUAD.
Identifiants
pubmed: 33850895
doi: 10.21037/atm-21-844
pii: atm-09-06-498
pmc: PMC8039684
doi:
Types de publication
Journal Article
Langues
eng
Pagination
498Informations de copyright
2021 Annals of Translational Medicine. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-21-844). The authors have no conflicts of interest to declare.
Références
Cancer Res. 2018 Jun 1;78(11):2839-2851
pubmed: 29588350
Gene. 2020 Apr 5;733:144273
pubmed: 31809842
Epigenetics. 2013 Apr;8(4):409-20
pubmed: 23478628
J Cell Physiol. 2020 May;235(5):4709-4719
pubmed: 31650535
Mol Cancer. 2018 Apr 7;17(1):79
pubmed: 29626935
J Transl Int Med. 2020 May 09;8(1):32-40
pubmed: 32435610
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
pubmed: 20610543
Cancer Lett. 2015 Sep 1;365(2):141-8
pubmed: 26052092
Cancer Lett. 2019 Sep 28;460:128-138
pubmed: 31207319
Aging (Albany NY). 2019 Nov 26;11(22):9982-9999
pubmed: 31772143
Cancer Lett. 2020 Feb 28;471:38-48
pubmed: 31811909
Oncol Lett. 2020 May;19(5):3578-3586
pubmed: 32269632
Life Sci. 2020 Oct 15;259:118157
pubmed: 32735888
Cancer Lett. 2018 May 28;422:70-80
pubmed: 29454093
Biochem Biophys Res Commun. 2020 Jan 8;521(2):395-401
pubmed: 31668923
Exp Ther Med. 2020 Feb;19(2):1112-1120
pubmed: 32010277
Zhongguo Fei Ai Za Zhi. 2020 Apr 20;23(4):223-232
pubmed: 32222154
Transl Lung Cancer Res. 2015 Apr;4(2):149-55
pubmed: 25870797
Cell Death Dis. 2020 Jul 27;11(7):593
pubmed: 32719345
Life Sci. 2019 Dec 15;239:116871
pubmed: 31521692
Cancer Lett. 2018 Jul 10;426:57-62
pubmed: 29654890
Mol Cell. 2015 Jun 4;58(5):870-85
pubmed: 25921068
Mol Cancer. 2019 Oct 17;18(1):145
pubmed: 31623628
Nature. 2013 Mar 21;495(7441):333-8
pubmed: 23446348
Int J Cancer. 2013 Nov 15;133(10):2277-83
pubmed: 23720067
RNA Biol. 2017 May 4;14(5):514-521
pubmed: 26649774
Semin Cancer Biol. 2018 Aug;51:116-128
pubmed: 28919484
Cancer Lett. 2018 Jul 10;426:37-46
pubmed: 29635069
Mol Cancer. 2019 Nov 21;18(1):166
pubmed: 31752867
Int J Mol Med. 2003 Feb;11(2):249-56
pubmed: 12525887
Cancer Lett. 2017 Sep 10;403:305-317
pubmed: 28687357
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593